登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688136 证券简称：科兴制药 公告编号：2025-091 科兴生物制药股份有限公司 关于向香港联交所递交H股发行上市申请 英文： https://www1.hkexnews.hk/app/sehk/2025/107843/documents/sehk25110601597.pdf 并刊发申请资料的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 科兴生物制药股份有限公司（以下简称"公司"）已于2025年11月6日向香港联合交易所有限公司（以下 简称"香港联交所"）递交了发行H股股票并在香港联交所主板挂牌上市（以下简称"本次发行上市"）的 申请，并于同日在香港联交所网站刊登了本次发行上市的申请材料。该申请材料为公司按照香港证券及 期货事务监察委员会（以下简称"香港证监会"）及香港联交所的要求编制和刊发，为草拟版本，其所载 资料可能会适时作出更新及修订，投资者不应根据其中的资料作出任何投资决定。 本次发行上市如果最终实施，发行对象将仅限于符合相关条件的境外投资 ...

Group 1 - Company Biao Bang Co., Ltd. has decided to terminate the planning of a change in control due to failure to reach consensus on key terms with the trading party, and will resume trading on November 7, 2025 [1] - Company Su Da Wei Ge plans to acquire 51% of Changzhou Weipu Semiconductor Equipment Co., Ltd. for 510 million yuan, making it a subsidiary [2] - Company Bei Ji Shen Zhou expects its revenue for 2025 to be between 36.2 billion yuan and 38.1 billion yuan, an increase from the previous forecast of 35.8 billion to 38.1 billion yuan [3] Group 2 - Company Hua Hong Semiconductor reported a revenue of approximately 12.58 billion yuan for the first three quarters of 2025, a year-on-year increase of 19.82% [4] - Company Jie Neng Wind Power plans to raise no more than 3.6 billion yuan through a private placement to fund various green power projects [5] - Company Zhen Ai Mei Jia is in the process of transferring control, with trading suspended since November 5, 2025, and expected to remain suspended for up to three trading days [7] Group 3 - Company Xin Hope plans to establish a joint venture with state-owned funds with a total registered capital of 2.87 billion yuan, where Xin Hope will contribute 2.1 billion yuan [8] - Company Yun Nan Ge Ye has approved a project to establish a new semiconductor materials company with an investment of 500 million yuan [8] - Company Tian Ci Materials has signed contracts for the supply of electrolyte products with two major clients, with expected total volumes of 87,000 tons and 72,500 tons for the years 2026-2028 [9][10]

Company Overview - Sinovac Biotech Ltd. (科兴生物制药股份有限公司) has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities International as the sole sponsor [1] - The company is an innovative and internationally developed biopharmaceutical firm focusing on the research, production, and commercialization of recombinant proteins, antibodies, and targeted delivery therapies [3] Product Portfolio - Sinovac's leading products include SINOGEN (人干扰素α1b注射液), EPOSINO (人促红素注射液), and WHITE-C (人粒细胞集落刺激因子注射液), which hold significant market shares in their respective segments [4] - SINOGEN is projected to capture approximately 55.2% of the short-acting interferon α1b market in China by 2024, while EPOSINO is expected to hold about 16.7% of the erythropoietin market [4] Financial Performance - The company's revenue from its main products for the years 2022, 2023, 2024, and the first half of 2025 is approximately RMB 1.314 billion, RMB 1.255 billion, RMB 1.392 billion, and RMB 680 million respectively [5] - Net profit figures for the same periods show a loss of RMB 92.82 million in 2022, a loss of approximately RMB 195.49 million in 2023, and a profit of RMB 27.05 million in 2024 [7] - The gross profit margin has been declining, recorded at 75.4% in 2022, 70.8% in 2023, and projected to be 63.6% in the first half of 2025 [8] Market Overview - The global pharmaceutical market is expected to grow from USD 1.324 trillion in 2019 to USD 1.671 trillion by 2024, with a projected CAGR of 3.8% reaching USD 2.0908 trillion by 2030 [10] - China's pharmaceutical market is also on the rise, anticipated to grow from RMB 1.633 trillion in 2019 to RMB 1.828 trillion by 2024, with a forecasted revenue of RMB 2.6245 trillion by 2030 [12] - The market for innovative biopharmaceuticals is expanding, with the global market size expected to reach USD 427.9 billion by 2024 and RMB 541.8 billion in China [13]

Company Overview - Kexing Biopharmaceutical Co., Ltd. (科兴制药) has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities International as the sole sponsor [1] - The company focuses on the research, production, and commercialization of innovative biopharmaceuticals, particularly in the fields of oncology and autoimmune diseases, addressing significant unmet clinical needs [2][3] Product Portfolio - Kexing's leading products include SINOGEN (人干扰素α1b注射液), EPOSINO (人促红素注射液), and WHITE-C (人粒细胞集落刺激因子注射液), which hold significant market shares in their respective segments [3] - SINOGEN is projected to capture approximately 55.2% of the short-acting interferon α1b market in China by 2024, maintaining its position as the top product for six consecutive years [3] - EPOSINO is expected to hold about 16.7% of the erythropoietin market, ranking second for four years [3] Financial Performance - Kexing's revenue from its main products was approximately RMB 13.14 billion, RMB 12.54 billion, RMB 13.92 billion, and RMB 6.80 billion for the years 2022, 2023, 2024, and the first half of 2025, respectively [4] - The company reported net profits of -RMB 92.82 million, -RMB 195.49 million, RMB 27.05 million, RMB 9.46 million, and RMB 78.96 million for the same periods [6] - Gross margins have shown a decline from 75.4% in 2022 to 63.6% in the first half of 2025 [7] Market Overview - The global pharmaceutical market is projected to grow from USD 1,324.4 billion in 2019 to USD 1,670.9 billion by 2024, with an expected CAGR of 3.8% until 2030 [11] - China's pharmaceutical market is also on the rise, anticipated to grow from RMB 1,633 billion in 2019 to RMB 1,828 billion by 2024, with a forecasted revenue of RMB 2,624.5 billion by 2030 [11] - The global market for innovative biopharmaceuticals is expected to reach USD 427.9 billion in 2024, with a CAGR of 8.4% projected until 2030 [14]

Company Overview - Sinovac Biotech Ltd. (科兴生物制药股份有限公司) has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities International as the sole sponsor [1] - The company is an innovation-driven biopharmaceutical firm focusing on the research, production, and commercialization of recombinant proteins, antibodies, and targeted delivery therapies, particularly in oncology and autoimmune diseases [4] Product Portfolio - Sinovac's leading products include SINOGEN (人干扰素α1b注射液), EPOSINO (人促红素注射液), and WHITE-C (人粒细胞集落刺激因子注射液), which hold significant market shares in their respective segments [5] - SINOGEN is projected to capture approximately 55.2% of the short-acting interferon α1b market in China by 2024, maintaining its position as the top product for six consecutive years [5] - EPOSINO is expected to hold about 16.7% of the erythropoietin market in China by 2024, ranking second for four years [5] Financial Performance - Revenue from key products for the years 2022, 2023, and 2024 is reported as approximately RMB 1.314 billion, RMB 1.254 billion, and RMB 1.392 billion, respectively [7] - The company achieved total revenues of approximately RMB 1.316 billion, RMB 1.259 billion, and RMB 1.407 billion for the fiscal years 2022, 2023, and 2024, respectively [8] - Net profit figures for the same periods were reported as losses of RMB 92.82 million in 2022, RMB 195.49 million in 2023, and a profit of RMB 27.05 million in 2024 [9] Market Overview - The global pharmaceutical market is projected to grow from USD 1.324 trillion in 2019 to USD 1.671 trillion by 2024, with a compound annual growth rate (CAGR) of 3.8% expected until 2030 [14] - China's pharmaceutical market is also on the rise, expected to grow from RMB 1.633 trillion in 2019 to RMB 1.828 trillion by 2024, with a forecasted revenue of RMB 2.624 trillion by 2030 [14] - The global market for innovative biopharmaceuticals is anticipated to reach USD 695.5 billion by 2030, with a CAGR of 8.4% from 2024 to 2030 [16]

证券代码：688136 证券简称：科兴制药 公告编号：2025-091 科兴生物制药股份有限公司 关于向香港联交所递交 H 股发行上市申请 并刊发申请资料的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科兴生物制药股份有限公司（以下简称"公司"）已于 2025 年 11 月 6 日向香 港联合交易所有限公司（以下简称"香港联交所"）递交了发行 H 股股票并在香港 联交所主板挂牌上市（以下简称"本次发行上市"）的申请，并于同日在香港联交 所网站刊登了本次发行上市的申请材料。该申请材料为公司按照香港证券及期货 事务监察委员会（以下简称"香港证监会"）及香港联交所的要求编制和刊发，为 草拟版本，其所载资料可能会适时作出更新及修订，投资者不应根据其中的资料 作出任何投资决定。 本次发行上市如果最终实施，发行对象将仅限于符合相关条件的境外投资者 及依据中国相关法律法规有权进行境外证券投资的境内合格投资者，公司将不会 在境内证券交易所的网站和符合监管机构规定条件的媒体上刊登该申请资料，但 为使境内投资者及时了解该等申请资料披露 ...

Core Viewpoint - The company, Sinovac Biotech (688136.SH), has submitted an application for issuing H-shares and listing on the Hong Kong Stock Exchange on November 6, 2025 [1] Group 1 - The application materials were published on the Hong Kong Stock Exchange website on the same day [1] - The materials were prepared in accordance with the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange [1] - The information contained in the application is a draft version and may be updated or revised in due course [1]

Core Insights - Kexing Biopharmaceutical Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Jinshi International as the sole sponsor [1] - The company is an innovative and internationally developed biopharmaceutical firm, focusing on the research, production, and commercialization of recombinant proteins, antibodies, and targeted delivery therapies [1] - Kexing is one of the earliest established biopharmaceutical companies in China and is a key industrialization base for the national "863" program [1] Revenue Sources - The main revenue sources during the reporting period include four self-commercialized products and two introduced products: - SINOGEN (Interferon α1b injection) - EPOSINO (Erythropoietin injection) - WHITE-C (Granulocyte colony-stimulating factor injection) - CLOBICO (Clostridium butyricum live bacteria powder/capsule) - Apexelsin (Paclitaxel injection) - Reminton (Infliximab injection) [1]

Core Viewpoint - The company, Sinovac Biotech Ltd., has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Jinshi International as its sole sponsor. The company is recognized as one of the earliest biopharmaceutical enterprises in China, focusing on the research, production, and commercialization of recombinant proteins, antibodies, and targeted delivery therapies [1]. Group 1 - Sinovac Biotech is an innovation-driven and internationally developed biopharmaceutical company [1]. - The company is one of the first biopharmaceutical enterprises established in China and is a key industrialization base for the national "863" program [1]. - The main revenue sources during the reporting period include four self-commercialized products and two introduced products [1]. Group 2 - The self-commercialized products include SINOGEN (human interferon α1b injection), EPOSINO (human erythropoietin injection), WHITE-C (human granulocyte colony-stimulating factor injection), and CLOBICO (Clostridium butyricum live bacteria powder/capsule) [1]. - The introduced products are Apexelsin (paclitaxel injection) and Reminton (infliximab injection) [1].

Core Viewpoint - Sinovac Biotech Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities International as the sole sponsor, highlighting its focus on innovative biopharmaceuticals and international development [1]. Group 1: Company Overview - Sinovac Biotech is an innovative and internationally developed biopharmaceutical company, specializing in the research, production, and commercialization of recombinant proteins, antibodies, and targeted delivery therapies [1]. - The company is one of the earliest established biopharmaceutical enterprises in China and is recognized as one of the first industrialization bases under the national "863" program [1]. Group 2: Revenue Sources - During the historical performance period, Sinovac Biotech's primary revenue sources include four self-commercialized products and two introduced products, which are: - SINOGEN (Interferon α1b injection) - EPOSINO (Erythropoietin injection) - WHITE-C (Granulocyte colony-stimulating factor injection) - CLOBICO (Clostridium butyricum live bacteria powder/capsule) - Apexelsin (Paclitaxel injection) - Reminton (Infliximab injection) [1].